A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

NCT03312738 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: Everolimus
DRUG: Exemestane
DRUG: Everolimus Placebo

Sponsor

Novartis Pharmaceuticals